Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： Shuangtao,Zhao

第一单位： Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

作者： Shuangtao,Zhao ^[1] ; Rashmi,Kanagal-Shamanna ^[2] ; Lucy,Navsaria ^[3] ; Chi Young,Ok ^[2] ; Shaojun,Zhang ^[1] ; Krystle,Nomie ^[3] ; Guangchun,Han ^[1] ; Dapeng,Hao ^[1] ; Holly A,Hill ^[3] ; Changying,Jiang ^[3] ; Yixin,Yao ^[3] ; Loretta,Nastoupil ^[3] ; Jason,Westin ^[3] ; Luis,Fayad ^[3] ; Ranjit,Nair ^[3] ; Raphel,Steiner ^[3] ; Sairah,Ahmed ^[3] ; Felipe,Samaniego ^[3] ; Swaminathan P,Iyer ^[3] ; Onyeka,Oriabure ^[3] ; Wendy,Chen ^[3] ; Xingzhi,Song ^[1] ; Jianhua,Zhang ^[1] ; Maria,Badillo ^[3] ; Omar,Moghrabi ^[3] ; Jorge,Aranda ^[3] ; Guilin,Tang ^[2] ; C Cameron,Yin ^[2] ; Keyur,Patel ^[2] ; Leonard Jeffrey,Medeiros ^[2] ; Shaoying,Li ^[2] ; Francisco,Vega ^[2] ; Selvi,Thirumurthi ^[4] ; Guofan,Xu ^[5] ; Sattva,Neelapu ^[3] ; Christopher R,Flowers ^[3] ; Jorge,Romaguera ^[3] ; Nathan,Fowler ^[3] ; Linghua,Wang ^[1] ; Michael L,Wang ^[3] ; Preetesh,Jain ^[3]

作者单位： Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[1] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[2] Department of Lymphoma and myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[3] Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[4] Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[5]